ConductScience.org, home

Trial · NCT07892196

Does Chronic Pain Change Over Time in Children With Duchenne Muscular Dystrophy?

NCT07892196, Recruiting, Antalya Training and Research Hospital

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Does Chronic Pain Change Over Time in Children With Duchenne Muscular Dystrophy? Trials, record NCT07892196. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07892196

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Does Chronic Pain Change Over Time in Children With Duchenne Muscular Dystrophy?
NCT number
NCT07892196
Status
Recruiting
Enrollment
30 participants, estimated
Lead sponsor
Antalya Training and Research Hospital
Conditions
Duchenne Muscular Dystrophy (DMD), Chronic Pain, Neuromuscular Diseases (NMD)
Interventions
Routine Clinical Follow-up and Pain Assessment
First posted
2026-10-23
Last updated
2026-10-23

Source ClinicalTrials.gov

Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryChange in Chronic Pain Intensity From Baseline to 6 MonthsBaseline (Month 0) and Month 6
Assessed using the Visual Analog Scale (VAS) component of the Adolescent Pediatric Pain Tool (APPT). Pain intensity is marked along a 100 mm horizontal line, where 0 mm indicates 'no pain' and 100 mm indicates 'worst possible pain'. Pain levels are categorized as: 0-4 mm (no pain), 5-44 mm (mild pain), 45-74 mm (moderate pain), and 75-100 mm (severe pain). Higher scores reflect greater pain severity.
SecondaryChange in Pain Interference on Daily Activities From Baseline to 6 MonthsBaseline (Month 0) and Month 6
ssessed using the 7-item Pain Interference Scale of the Brief Pain Inventory (BPI). It evaluates how much pain interferes with 7 daily life domains (general activity, mood, walking ability, normal work, relations with others, sleep, and enjoyment of life) over the past 24 hours. Each item is rated on an 11-point numeric scale from 0 (does not interfere) to 10 (completely interferes). The total score ranges from 0 to 70, with higher scores indicating greater pain interference in daily functioning.
SecondaryChange in the Number of Anatomical Pain Sites From Baseline to 6 MonthsBaseline (Month 0) and Month 6
Assessed using the pediatric body diagram of the Adolescent Pediatric Pain Tool (APPT). Participants mark all anatomical regions where they experience pain. The total number of painful body areas is quantified, with higher numbers indicating more widespread pain.
SecondaryChange in Pain Quality Descriptors From Baseline to 6 MonthsBaseline (Month 0) and Month 6
Assessed using the word descriptor component of the Adolescent Pediatric Pain Tool (APPT), which evaluates 4 dimensions of pain quality: sensory, affective, evaluative, and temporal across a total of 15 words. Scores are calculated as percentages of selected words relative to the total number of words within each dimension (0% to 100%). Higher percentage scores indicate greater endorsement of that specific pain dimension.
SecondaryChange in Pediatric Pain Coping Strategies From Baseline to 6 MonthsBaseline (Month 0) and Month 6
Assessed using the Pediatric Pain Coping Inventory (PPCI, adolescent and parent-proxy versions). It measures coping strategies across 5 subscales: cognitive self-instruction, problem solving, distraction, seeking social support, and catastrophizing/helplessness. Items are scored on a 3-point Likert scale (0 = never, 1 = sometimes, 2 = often). Higher scores in each subscale indicate more frequent utilization of that specific coping strategy.
SecondaryChange in Ambulatory Motor Performance From Baseline to 6 MonthsBaseline (Month 0) and Month 6
Assessed using the North Star Ambulatory Assessment (NSAA) in ambulatory participants. It evaluates 17 motor activities (such as standing, walking, rising from a chair, jumping, and running). Each item is scored on a 3-point scale: 0 (unable to achieve independently), 1 (achieves with modifications), and 2 (normal performance). Total raw scores range from 0 to 34, with higher scores reflecting better motor and functional capability.
SecondaryChange in Functional Exercise Capacity From Baseline to 6 MonthsBaseline (Month 0) and Month 6
Evaluated using the modified 6-Minute Walk Test (6MWT) according to standard DMD protocols in ambulatory participants capable of walking at least 75 meters. Total distance walked in 6 minutes is recorded in meters. A greater distance indicates better functional exercise tolerance.
SecondaryChange in Lower and Upper Extremity Functional Disability Stages From Baseline to 6 MonthsBaseline (Month 0) and Month 6
Lower extremity function is evaluated using the Vignos Scale (grades 1 to 10, ranging from 1 = walks and climbs stairs without assistance to 10 = bedridden). Upper extremity function is evaluated using the Brooke Scale (grades 1 to 6, ranging from 1 = arms abducted in a full circle to touch above head to 6 = no useful hand function). For both scales, higher numerical scores indicate more severe functional disability.
SecondaryChange in Muscle Strength From Baseline to 6 MonthsBaseline (Month 0) and Month 6
Handgrip strength is measured bilaterally using an electronic hand dynamometer in kilograms (kg), recording the average and maximum of 3 trials. Proximal and distal muscle strength is assessed bilaterally using Manual Muscle Testing (MMT) with the Medical Research Council (MRC) scale (0 = no movement to 5 = normal strength). Total muscle strength is calculated as a composite percentage score (%MRC) using the standard formula: (Total score × 100) / (Number of tested muscles × 5). Higher values indicate greater muscle strength.
SecondaryChange in Timed Stair Climbing and Descending Performance From Baseline to 6 MonthsBaseline (Month 0) and Month 6
Timed performance to ascend and descend a standard 4-step flight of stairs is measured in seconds using a digital stopwatch. Shorter completion times indicate superior functional mobility and lower extremity motor velocity.

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07892196

GET https://conductscience.org/api/trials/v1/NCT07892196/registered